Extended Data Fig. 3: RBM42 loss does not alter Myc protein stability or RNA splicing.
From: Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity
(a) Myc protein cycloheximide (CHX) stability assay quantification and representative western blots in Panc-1 cells, n = 3 independent experiments. Both bands were quantified for Myc protein levels. P-value of the difference between the slopes of a simple linear regression. Values under blot indicate normalized Myc protein expression relative to shCNTL; mean ± SD. (b) qPCR quantification of retained introns for MYC and control mRNA B2M, n = 3. Two-way ANOVA, uncorrected Fisher’s LSD test. (c) Panc-1 shCNTL and shRBM42 RNA-seq global splicing analysis (rMATS) collapsed to gene level, graphing the event with the highest ΔPSI, (n = 3 replicates/condition). Table events FDR < 0.05 and |ΔPSI| > 0.1. (d) Additional human patient PDAC specimen RBM42 immunohistochemistry (IHC). Disease grade (G) and stage, where reported, are listed. Representative image of at least 3 fields per patient. Scale bars, 50 μm. (e) Representative western blots of cytoplasmic and nuclear fractionation of pancreatic cancer cell lines. Western blot representative of 3 independent experiments. Graphs are mean ± SEM unless otherwise noted. Extended data associated with Fig. 2.
